Yarrow Bioscience And VYNE Therapeutics Compete Merger With Previously Announced Private Financings Totaling ~$200M; To Operate As Yarrow Bioscience And Trade On Nasdaq Capital Market From July 28 Under Ticker Symbol 'YARW'

Yarrow is advancing YB-101—a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves’ disease ("GD") and thyroid eye disease ("TED")

Dosing commenced in Phase 2a/2b GD trial following FDA Fast Track Designation, with Phase 2a data expected in 2H 2027

Data from ongoing Phase 1 multiple ascending dose ("MAD") trial in patients with TED, conducted by partner, GenSci, in China expected in 2H 2027